Elizabeth Mormino, PhD Linkedin Google Dr. Beth Mormino completed a PhD in Neuroscience at UC Berkeley in the laboratory of Dr. William Jagust, where she performed some of the initial studies applying Amyloid PET with the tracer PIB to clinically normal older individuals. This initial work provided evidence that the pathophysiological processes of Alzheimer’s disease […]
Joe Abisambra, PhD Linkedin Twitter Google I obtained a BS in Biology (2002) at Saint Leo University in FL, and then relocated to Tampa, FL, where I earned a MS in Biochemistry and Molecular Biology (2004). I then joined Dr. Huntington Potter’s lab at the Byrd Alzheimer’s Institute, which was affiliated with USF, and defended
Katherine Bangen, PhD Linkedin Google Dr. Bangen completed her doctoral training at the San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology. Her research aims to better understand the functional and structural brain changes that occur in normal aging, mild cognitive impairment, and dementia. Her current projects utilize neuropsychological and
Timothy J. Hohman, PhD Linkedin Twitter Google Dr. Timothy Hohman is an Assistant Professor of Neurology and a cognitive neuroscientist. He received his doctoral degree in neuroscience from American University focusing on cognitive and neural changes during normal aging. He also completed a fellowship as part of the National Institutes of Health Graduate Partnership Program
Ai-Ling Lin, PhD Google Dr. Ai-Ling Lin is the Vice Chair for Research of the Department of Radiology, Professor of Radiology, Biological Sciences, and Institute for Data Science & Informatics, and a Principal Investigator at the NextGen Precision Health Institute at the University of Missouri- Columbia. Originally from Taiwan, Dr. Lin completed her PhD and Postdoctoral training as a
Rodrigo Medeiros, PhD Since 2007, Rodrigo has led the effort to identify the underlying mechanisms related with the development and progression of neurodegenerative diseases. His long-term goal is to advance knowledge of healthy, and diseased, brain function to a point where rational strategies can be developed for the prevention and cure of age-related neurological disorders.
Peter Davies, PhD We are deeply saddened by the loss of a great friend and one of Alzheimer’s brilliant scientific minds. Peter Davies will be forever remembered by the CCAD family. It is not the most distinguished achievements that men’s virtues or vices may be best discovered; but very often an action of small note.
Ralph Nixon, MD, PhD Dr. Ralph Nixon currently serves as Vice Chairman on the Medical and Scientific Advisory Board of the national Alzheimer’s Association and on the Governor’s Commission on Alzheimer’s Disease for the State of New York. Dr. Nixon’s work is the first to call attention to the importance of proteases in Alzheimer’s disease.
Alison Goate, DPhil Dr. Goate is a renowned neuropsychiatric researcher and molecular geneticist whose pioneering work falls within two areas: gene discovery and modeling disease mutations. She is best known for identifying the first gene mutation linked to an inherited form of Alzheimer’s disease, and for finding common and rare variants that influence the risk
